dehydroepiandrosterone sulfate and docetaxel anhydrous

dehydroepiandrosterone sulfate has been researched along with docetaxel anhydrous in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Agus, DB; Bargfrede, M; Carthon, B; Clark, WR; Gandhi, JG; Heath, E; Kong, N; Lin, J; Liu, G; Moran, S; Oh, WK; Petrylak, DP; Suri, A	1
Alsinnawi, M; Balk, S; Bianchi-Frias, D; Burns, J; Cho, E; Montgomery, RB; Mostaghel, EA; Nelson, PS; Porter, C; Slee, AE; Sowalsky, A; Taplin, ME; True, L; Ye, H; Zhang, A; Zhang, X	1

Trials

1 trial(s) available for dehydroepiandrosterone sulfate and docetaxel anhydrous

Article	Year
Phase 1/2 study of orteronel (TAK-700), an investigational 17,20-lyase inhibitor, with docetaxel-prednisone in metastatic castration-resistant prostate cancer. Investigational new drugs, 2015, Volume: 33, Issue:2 Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Dehydroepiandrosterone Sulfate; Disease Progression; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Humans; Imidazoles; Male; Middle Aged; Naphthalenes; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Steroid 17-alpha-Hydroxylase; Taxoids; Testosterone	2015

Article

Year

Phase 1/2 study of orteronel (TAK-700), an investigational 17,20-lyase inhibitor, with docetaxel-prednisone in metastatic castration-resistant prostate cancer.

Investigational new drugs, 2015, Volume: 33, Issue:2

Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Dehydroepiandrosterone Sulfate; Disease Progression; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Humans; Imidazoles; Male; Middle Aged; Naphthalenes; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Steroid 17-alpha-Hydroxylase; Taxoids; Testosterone

2015

Other Studies

1 other study(ies) available for dehydroepiandrosterone sulfate and docetaxel anhydrous

Article	Year
Association of prostate cancer SLCO gene expression with Gleason grade and alterations following androgen deprivation therapy. Prostate cancer and prostatic diseases, 2019, Volume: 22, Issue:4 Topics: Adult; Aged; Androgen Antagonists; Androstenes; Dehydroepiandrosterone Sulfate; Disease Progression; Docetaxel; Follow-Up Studies; Gene Expression Regulation, Neoplastic; Humans; Male; Middle Aged; Neoplasm Grading; Organic Anion Transporters; Prostate; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms, Castration-Resistant; Solute Carrier Organic Anion Transporter Family Member 1B3; Testosterone; Treatment Outcome	2019

Article

Year

Association of prostate cancer SLCO gene expression with Gleason grade and alterations following androgen deprivation therapy.

Prostate cancer and prostatic diseases, 2019, Volume: 22, Issue:4

Topics: Adult; Aged; Androgen Antagonists; Androstenes; Dehydroepiandrosterone Sulfate; Disease Progression; Docetaxel; Follow-Up Studies; Gene Expression Regulation, Neoplastic; Humans; Male; Middle Aged; Neoplasm Grading; Organic Anion Transporters; Prostate; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms, Castration-Resistant; Solute Carrier Organic Anion Transporter Family Member 1B3; Testosterone; Treatment Outcome

2019